• 1
    Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001; 58: 10813
  • 2
    Byar DP. Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 112630
  • 3
    Shamash J, Stebbing J, Sweeney C et al. A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer 2010; 116: 3595602
  • 4
    Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer 2009; 7: E716
  • 5
    Robinson MR, Thomas BS. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. BMJ 1971; 4: 3914
  • 6
    Geisler J, Haynes B, Anker G et al. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 2005; 96: 41522
  • 7
    Geier R, Adler S, Rashid G, Klein A. The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells. Prostate 2010; 70: 130712
  • 8
    Wang H, Li J, Gao Y et al. Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor. Asian J Androl 2010; 12: 53547
  • 9
    The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 10117
  • 10
    Prout GR, Kliman B, Daly JJ, MacLaughlin RA, Griffin PP, Young HH. Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitary-gonadal axis. Urology 1976; 7: 14855
  • 11
    Kent JR, Bischoff AJ, Arduino LJ et al. Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J Urol 1973; 109: 85860
  • 12
    Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998; 52: 25760
  • 13
    Clemons J, Glodé LM, Gao D, Flaig TW. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urol Oncol 2011; doi:10.1016/j.urolonc.2010.12.004
  • 14
    Orlando M, Chacon M, Salum G, Chacon DR. Low-dose continuous oral fosfestrol is highly active in ‘hormone-refractory’ prostate cancer. Ann Oncol 2000; 11: 17781
  • 15
    Rosenbaum E, Carducci MA. Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges. Expert Opin Pharmacother 2003; 4: 87587
  • 16
    Chang A, Yeap B, Davis T et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996; 14: 22507
  • 17
    Klotz L, McNeill I, Fleshner N. A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999; 161: 16972
  • 18
    Bishop MC. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. BJU Int 1996; 78: 9218
  • 19
    Serrate C, Loriot Y, De La Motte Rouge T et al. Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Ann Oncol 2009; 20: 965
  • 20
    Attard G, Reid AHM, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 456371
  • 21
    Molina A, Belldegrun A. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011; 185: 78794
  • 22
    Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 78790
  • 23
    Huggins CB. Propositions in hormonal treatment of advanced cancers. JAMA 1965; 192: 11415
  • 24
    Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Sumiyoshi A. The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer. Prostate 1992; 21: 35 9
  • 25
    de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986; 135: 3037
  • 26
    Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R. The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995; 28: 27383
  • 27
    Waymont B, Lynch TH, Dunn JA et al. Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. BJU Int 1992; 69: 61420
  • 28
    Manikandan R, Srirangam SJ, Pearson E, Brown SCW, O'Reilly P, Collins GN. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Urol Int 2005; 75: 21721
  • 29
    Azoulay L, Yin H, Benayoun S, Renoux C, Boivin J-F, Suissa S. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 2011; 60: 124450
  • 30
    Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003; 61: 1424